Advertisement

Lasers in Medical Science

, Volume 3, Issue 1–4, pp 1–6 | Cite as

Photodynamic therapy of C3H tumours in mice: Effect of drug/light dose fractionation and misonidazole

  • Jan F. Evensen
  • Johan Moan
Article

Abstract

C3H mammary carcinomas transplanted to the feet of mice were treated with haematoporphyrin derivative (HPD) or Photofrin II(PII) and laser light at 630 nm. While fluence rates lower than 100 mW cm−2 gave minimal hyperthermic effects, a slight but significant growth delay was observed in unsensitized tumours exposed to a fluence rate of 150 mW cm−2 which induced tumour temperatures in the range 40–50°C. Different modes of fractionation of the light fluence and of the HPD dose were tested but were found to give poorer rather than better results than the application of a single light exposure 24 h after intraperitoneal injection of HPD. Different PII doses were applied together with different light fluences, keeping the product of the drug dose and light fluence constant. In the dose range 6.25–50 mg/kg body weight the resulting effect on tumours was constant, allowing for a slight effect of hyperthermia at the highest light fluences, and possibly a photodegradation of PII. Misonidazole given before photodynamic treatment (PDT) slightly reduced the effect of PDT on the tumour growth. When given after PDT, however, misonidazole improved the therapeutic results significantly.

Key words

Photodynamic therapy Hyperthermia Fractiontation Misonidazole C3H tumour 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Evensen JF, Sommer S, Rimington C, Moan J. Photodynamic therapy of C3H mouse mammary carcinoma with haematoporphyrin di-ethers as sensitizers.Br J Cancer 1987,55: 482–6Google Scholar
  2. 2.
    Evensen JF, Moan J. A test of different photoseesitizers for photodynamic treatment of cancer in a murine tumor model.Photochem Photobiol 1987,46: 859–66.PubMedGoogle Scholar
  3. 3.
    Hall EJ.Radiobiology for the radiologist, 2nd edn. Philadelphia: Harper & Row, 1978Google Scholar
  4. 4.
    Lipson RL, Baldes E, Olsen A. The use of a derivative of hematoporyphyrin in tumor detection.J. Natl Cancer Inst 1960,26: 1–11Google Scholar
  5. 5.
    Begg AC. Analysis of growth delay data: potential pitfalls.Br J Cancer 1980,41, Supplement IV: 93–7Google Scholar
  6. 6.
    Peto R, Peto J. Asymptomatically efficient rank invariant test procedures.J R Statist Soc 1972,A135: 185–207Google Scholar
  7. 7.
    Kinsey JH, Cortese DA, Neel HB. Thermal considerations in murine tumor killing using hematoporphyrin derivative phototherapy.Cancer Res 1983,43: 1562–7PubMedGoogle Scholar
  8. 8.
    Moan J. Effect of bleaching of porphyrin sensitizers during photodynamic therapy.Cancer Letters 1986,33: 45–53PubMedCrossRefGoogle Scholar
  9. 9.
    Mang TS, Dougherty TJ, Potter WR et al. Photobleaching of porphyrins used in photodynamic therapy and implications for therapy.Photochem Photobiol 1987,45: 501–6PubMedGoogle Scholar
  10. 10.
    Christensen T, Wahl A, Smedshammer L. Effects of haematoporphyrin derivative and light in combination with hyperthermia on cells in culture.Br J Cancer 1985,50: 85–9Google Scholar
  11. 11.
    Mang TS, Dougherty TJ. Time and sequence dependent influence of in vitro photodynamic therapy (PDT) survival by hyperthermia.Photochem Photobiol 1985,42: 533–40PubMedGoogle Scholar
  12. 12.
    Waldow SM, Henderson BW, Dougherty TJ. Potentiation of photodynamic therapy by heat: effect of sequence and time interval between treatments in vivo.Lasers Surg Med 1985,5: 83–94PubMedCrossRefGoogle Scholar
  13. 13.
    Gomer CJ, Dougherty TJ. Determination of (3H)- and (14C)-hematoporphyrin derivative distribution in malignant and normal tissue.Cancer Res 1979,39: 146–51PubMedGoogle Scholar
  14. 14.
    Star WM, Marijnissen HPA, van den Berg-Blok AE et al. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers.Cancer Res 1986,46: 2532–40PubMedGoogle Scholar
  15. 15.
    Lee See K, Forbes IJ, Bells WH. Oxygen dependency of photocytotoxicity with hematoporphyrin derivative.Photochem Photobiol 1984,39: 631–4PubMedGoogle Scholar
  16. 16.
    Moan J, Sommer S. Oxygen dependence of the photosen-sitizing effect of hematoporphyrin derivative in NHIK 3025 cells.Cancer Res 1985,45: 1608–10PubMedGoogle Scholar
  17. 17.
    Moan J, Christensen T. Cellular uptake and photodynamic effect of hematoporphyrin.Photobiochem Photobiophys 1981,2: 291–9Google Scholar
  18. 18.
    Hall EJ, Astor M, Geard C, Biaglow J. Cytotoxicity of Ro-07-0582: enhancement by hyperthermia and protection by cysteamine.Br J Cancer 1977,35: 809–15PubMedGoogle Scholar
  19. 19.
    Stratford IJ, Adams GE. Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro.Br J Cancer 1977,35: 307–13PubMedGoogle Scholar
  20. 20.
    Kraljic' I, ElMohsni S. A new method for the detection of singlet oxygen in aqueous solutions.Photochem Photobiol 1978,28: 577–81Google Scholar
  21. 21.
    Gonzalez S, Arnfield MR, Meeker BE et al. Treatment of dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole.Cancer Res 1986,46: 2858–62PubMedGoogle Scholar
  22. 22.
    Graschew G, Shopova M. Hypoxia, misonidazole and hyperthermia in photodynamic therapy of tumors.Lasers Med Sci 1986,1: 181–6CrossRefGoogle Scholar
  23. 23.
    Bicher HI, Hetzel FW, Sandhu TS, Frinak S. Oxygen and pH in tumors; inhomogeneous distributions, effect of hyperthermia and phototherapy. 29th Annual Meeting of the Radiation Research Society, Minneapolis, 1981Google Scholar

Copyright information

© Baillière Tindall 1988

Authors and Affiliations

  • Jan F. Evensen
    • 1
  • Johan Moan
    • 1
  1. 1.Institute for Cancer Research, Department of BiophysicsThe Norwegian Radium HospitalOslo 3Norway

Personalised recommendations